Skip to main content

Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation.

Publication ,  Journal Article
Eron, JJ; Bartlett, JA; Santana, JL; Bellos, NC; Johnson, J; Keller, A; Kuritzkes, DR; St Clair, MH; Johnson, VA
Published in: J Acquir Immune Defic Syndr
December 15, 2004

Antiretroviral (ARV) treatment decisions are difficult for HIV-1-infected patients on complex treatment regimens who have partial suppression of HIV-1 replication and limited treatment options. Information on the ARV activity of the components of a complex regimen would be useful. Sixteen subjects who had received prolonged therapy with zidovudine (ZDV) and lamivudine (3TC), with a median duration of 32.5 months, were discontinuing this dual-nucleoside regimen and volunteered to have plasma HIV-1 RNA levels monitored over the 2 weeks after discontinuation. All subjects experienced an increase in HIV-1 RNA after discontinuation, with a median increase of 0.54 log10 copies/mL over 2 weeks (range: 0.31-1.71; P < 0.001). An inverse correlation existed between the decline in HIV-1 RNA levels over 2 to 3 years on nucleoside analogue therapy and the increase over the 10 to 14 days off therapy (Spearman r = -0.53; P = 0.036). Over the 2-week period, a subset of individuals who had genotype testing at multiple reverse transcriptase codons associated with ZDV and 3TC resistance had no changes in genotype off therapy. Nucleoside analogue reverse transcriptase inhibitors may have continued ARV activity despite long durations of partially suppressive therapy and the presence of resistant HIV-1.

Duke Scholars

Published In

J Acquir Immune Defic Syndr

DOI

ISSN

1525-4135

Publication Date

December 15, 2004

Volume

37

Issue

5

Start / End Page

1581 / 1583

Location

United States

Related Subject Headings

  • Zidovudine
  • Virology
  • Treatment Outcome
  • Time Factors
  • Reverse Transcriptase Inhibitors
  • RNA, Viral
  • Lamivudine
  • Humans
  • HIV-1
  • HIV Infections
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Eron, J. J., Bartlett, J. A., Santana, J. L., Bellos, N. C., Johnson, J., Keller, A., … Johnson, V. A. (2004). Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J Acquir Immune Defic Syndr, 37(5), 1581–1583. https://doi.org/10.1097/00126334-200412150-00009
Eron, Joseph J., John A. Bartlett, Jorge L. Santana, Nicholas C. Bellos, Judy Johnson, Amy Keller, Daniel R. Kuritzkes, Marty H. St Clair, and Victoria A. Johnson. “Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation.J Acquir Immune Defic Syndr 37, no. 5 (December 15, 2004): 1581–83. https://doi.org/10.1097/00126334-200412150-00009.
Eron JJ, Bartlett JA, Santana JL, Bellos NC, Johnson J, Keller A, et al. Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1581–3.
Eron, Joseph J., et al. “Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation.J Acquir Immune Defic Syndr, vol. 37, no. 5, Dec. 2004, pp. 1581–83. Pubmed, doi:10.1097/00126334-200412150-00009.
Eron JJ, Bartlett JA, Santana JL, Bellos NC, Johnson J, Keller A, Kuritzkes DR, St Clair MH, Johnson VA. Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1581–1583.

Published In

J Acquir Immune Defic Syndr

DOI

ISSN

1525-4135

Publication Date

December 15, 2004

Volume

37

Issue

5

Start / End Page

1581 / 1583

Location

United States

Related Subject Headings

  • Zidovudine
  • Virology
  • Treatment Outcome
  • Time Factors
  • Reverse Transcriptase Inhibitors
  • RNA, Viral
  • Lamivudine
  • Humans
  • HIV-1
  • HIV Infections